Related Experiment Video
Updated: Jul 7, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and
Zhengjun Yang1,2,3,4, Yuqing Dai5, Yinuo Li6
1The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
Background:
Pathologic complete response (pCR) after neoadjuvant chemotherapy and dual HER2 blockade is associated with improved outcomes in HER2-positive breast cancer, but treatment response remains heterogeneous. We aimed to develop and externally validate an interpretable model based on routine clinicopathological biomarkers to predict pCR and identify clinically meaningful response states.
Methods:
In this multicenter retrospective study, 1,082 patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade at two Chinese centers were included for model development and internal validation. An independent cohort of 307 patients from a third center was used for external validation. Machine-learning models were developed using routinely available pretreatment clinicopathological variables. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Probability-landscape analyses were performed to characterize biomarker-defined response states associated with pCR.
Results:
The final gradient boosting machine model achieved AUCs of 0.78 in internal testing and 0.70 in external validation. Probability-landscape analyses identified distinct response states with substantially different pCR probabilities. Low hormone receptor expression combined with HER2 immunohistochemistry (IHC) 3 + status defined a high-probability pCR state, whereas high hormone receptor expression, low Ki-67 expression, and HER2 IHC 2+/fluorescence in situ hybridization (FISH)-positive disease defined persistently low-probability states. Among baseline node-positive patients who achieved breast pCR, residual nodal disease was observed in only 6.1% of cases.
Conclusions:
Routine clinicopathological biomarkers can be integrated into an interpretable machine-learning model to predict pCR and enable scalable response probability mapping in HER2-positive breast cancer receiving neoadjuvant chemotherapy and dual HER2 blockade. This approach may facilitate individualized treatment selection and support future treatment-adaptation and surgical de-escalation strategies.
